Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™, and the leading third-party support provider for Oracle, SAP and VMware software, today introduced Rimini Agentic UX™, an intelligent, AI-driven user engagement layer that streamlines ERP process execution for efficiency and significant savings, delivering persona- and role-based automation and productivity enhancements without the need for costly ERP Software upgrades or migrations. This press release feature...

Global Critical Logistics (GCL) announced today its brand evolution into the newly unveiled identity of The Rock-It Company, uniting its diverse portfolio under the iconic and globally recognized name. The announcement arrives as Rock-It delivers some of the world’s most impactful cultural moments this week including the Final Draw of the FIFA World Cup 2026™ in Washington D.C., Art Basel in Miami, The Conference at Rock Lititz and several concerts and automotive events in Abu Dhabi, including ...

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with r...

The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and com...

Takeda (TSE:4502/NYSE:TAK) today announced positive topline results for the two pivotal Phase 3 randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and P...